- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00973492
Impact of Functional Insulinotherapy on Blood Glucose Variability Indicators in Patients With Type 1 Diabetes (VARIAFIT)
The primary objective of this trial is to assess whether functional insulinotherapy decreases blood glucose variability at 3 months and 6 months, compared to initial values in type 1 diabetes patients.
So, this study measures the impact of functional insulinotherapy on several blood glucose variability indicators in patients with type 1 diabetes.
This trial also has a secondary objective: to measure the effect of functional insulinotherapy on oxidative stress and inflammation.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a prospective, open, non-controlled study with an individual benefit for the participant. This study is designed to assess whether functional insulinotherapy decreases blood glucose variability at 3 months and 6 months, compared to initial values in type 1 diabetes patients.
All 30 patients with type 1 diabetes attended a 4-day functional insulinotherapy class, taught by 2 nurses, 2 dieticians and 2 physicians. The participants were recruited among metabolically stable patients who had already been prescribed functional insulinotherapy.
To assess the impact of functional insulinotherapy on blood glucose variability, HbA1c will be measured at 0, 3 months and 6 months along with 4 blood glucose variability indicators: MAGE, ADRR, LI and LBGI.
This trial also has a secondary objective: to measure the effect of functional insulinotherapy on oxidative stress. Therefore, a measure of insulin antibodies by ELISA at baseline. At baseline and 6 months, LTE4, TXB2, 8-iso-PGF2alpha, anti-transglutaminase and anti-endomysium antibodies will also be assessed.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
-
Grenoble Cedex 9, Frankrig, 38043
- Service de Diabétologie du Pr Halimi, CHU
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Patients with type 1 diabetes with pump or multi-injection treatment and attending a functional insulinotherapy class
- Social Security membership or benefit from Social Security
- Informed consent, with a signed and approved form
Exclusion Criteria:
- Underage patient, major patient under guardianship or protected by the Law
- Pregnant, parturient or breastfeeding woman
- Person with no freedom (prisoner), person in an emergency situation, person hospitalized without consent and not protected by the Law
- Antecedents of pathologies causing diabetes instability (coeliac disease, gastroparesis, non-balanced psychiatric pathology) and not optimally treated, acute pathology less than 3 months ago (infectious, cardio-vascular, metabolic), pregnancy
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
patients with functional insulinotherapy
There is only one group in this study.
The participants will attend a functional insulinotherapy class.
|
The functional insulinotherapy class lasts for 4 days. It is taught by 2 nurses, 2 dieticians and 2 physicians to 6 to 10 patients. On day 1, patients describe their difficulties with diabetes. Fast-acting insulin scales are elaborated from preprandial and postprandial blood glucose levels. At dinner, patients start a 24-hour glucose-fasting period to evaluate their need for basal insulin. Meals contain virtually no carbohydrates. Correcting doses of insulin are administered if preprandial glycemia is over 1.50 g/l or postprandial glycemia is over 2 g/l. Blood glucose levels must stay within normal values during the whole 24-hour period. Carbohydrate management is taught during meals and every afternoon through workshops about dietetics. Patients also learn how to deal with hypoglycaemia, hyperglycaemia and physical activity. A one-day follow-up takes place 3 months later. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
MAGE, ADRR, Lability Index and LBGI computed with the blood glucose measurement or CGMS
Tidsramme: 0, 3 months, 6 months
|
0, 3 months, 6 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
anti-transglutaminase and anti-endomysium antibodies
Tidsramme: 0 months, 6 months
|
0 months, 6 months
|
dosage of urinary leucotriene E4 and 11-dehydro-thromboxane B2, 8-iso-PGF2alpha
Tidsramme: 0 months, 6 months
|
0 months, 6 months
|
anti-insulin antibodies by ELISA
Tidsramme: 0 months
|
0 months
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Pierre-Yves Benhamou, PhD, University Hospital, Grenoble
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2007-A00903-50
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Type 1 diabetes
-
Oxford Brookes UniversityUniversity of OxfordAfsluttetFysisk aktivitet | Mental sundhed velvære 1 | Kognitiv funktion 1, Social | Academic Attainment | Fitness TestingDet Forenede Kongerige
-
Merck Sharp & Dohme LLCRekrutteringIkke-småcellet lungekræft | Faste tumorer | Programmeret celledød-1 (PD1, PD-1) | Programmeret celledød 1 Ligand 1 (PDL1, PD-L1) | Programmeret celledød 1 ligand 2 (PDL2, PD-L2)Japan
-
Alvotech Swiss AGAfsluttet
-
PfizerAfsluttet
-
Stony Brook UniversityAfsluttet
-
SanionaAfsluttet
-
Calliditas Therapeutics ABEurofins Optimed; York Bioanalytical SolutionAfsluttet
-
Calliditas Therapeutics ABAfsluttet
-
JKT Biopharma Co., Ltd.Rekruttering
-
Graviton Bioscience CorporationAfsluttet
Kliniske forsøg med functional insulinotherapy class
-
Medical Research CouncilUkendtSelvskadende adfærdDet Forenede Kongerige
-
University of California, San FranciscoNational Institute of Mental Health (NIMH); University of California, BerkeleyAfsluttetAttention Deficit Disorder med hyperaktivitetForenede Stater
-
IRCCS Eugenio MedeaRekrutteringFor tidlig fødsel | Forældre-barn relationerItalien
-
Milton S. Hershey Medical CenterRekrutteringMobilitetsbegrænsning | Gå, besværForenede Stater
-
Recep Tayyip Erdogan University Training and Research...AfsluttetMuskelstyrke | Sportsskade | MuskelkontraktionKalkun
-
University of BeykentAfsluttet
-
University Hospital, Basel, SwitzerlandAfsluttet
-
Washington University School of MedicineMerck Sharp & Dohme LLCAfsluttet
-
The Institute for Functional MedicineFunctional Medicine Coaching AcademyAfsluttet
-
Spaulding Rehabilitation HospitalAfsluttetRygmarvsskadeForenede Stater